Levetiracetam Prophylaxis for Post-traumatic Brain Injury Seizures is Ineffective: A Propensity Score Analysis.
Early seizures after severe traumatic brain injury (TBI) have a reported incidence of up to 15 %. Prophylaxis for early seizures using 1 week of phenytoin is considered standard of care for seizure prevention. However, many centers have substituted the anticonvulsant levetiracetam without good data on the efficacy of this approach. Our hypothesis was that the treatment with levetiracetam is not effective in preventing early post-traumatic seizures.



All trauma patients sustaining a TBI from January 2007 to December 2009 at an urban level-one trauma center were retrospectively analyzed. Seizures were identified from a prospectively gathered morbidity database and anticonvulsant use from the pharmacy database. Statistical comparisons were made by Chi square, t tests, and logistic regression modeling. Patients who received levetiracetam prophylaxis were matched 1:1 using propensity score matching with those who did not receive the drug.



5551 trauma patients suffered a TBI during the study period, with an overall seizure rate of 0.7 % (39/5551). Of the total population, 1795 were diagnosed with severe TBI (Head AIS score 3-5). Seizures were 25 times more likely in the severe TBI group than in the non-severe group [2.0 % (36/1795) vs. 0.08 % (3/3756); OR 25.6; 95 % CI 7.8-83.2; p < 0.0001]. Of the patients who had seizures after severe TBI, 25 % (9/36) received pharmacologic prophylaxis with levetiracetam, phenytoin, or fosphenytoin. In a matched cohort by propensity scores, no difference was seen in seizure rates between the levetiracetam group and no-prophylaxis group (1.9 vs. 3.4 %, p = 0.50).



In this propensity score-matched cohort analysis, levetiracetam prophylaxis was ineffective in preventing seizures as the rate of seizures was similar whether patients did or did not receive the drug. The incidence of post-traumatic seizures in severe TBI patients was only 2.0 % in this study; therefore we question the benefit of routine prophylactic anticonvulsant therapy in patients with TBI.
Department of Surgery, University of Arizona, Tucson, AZ, USA.
Bardiya
B
Zangbar
Department of Surgery, University of Arizona, Tucson, AZ, USA.
Mazhar
M
Khalil
Department of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA.
Angelika
A
Gruessner
Department of Surgery, University of Arizona, Tucson, AZ, USA.
Bellal
B
Joseph
Department of Surgery, University of Arizona, Tucson, AZ, USA.
Randall
R
Friese
Department of Surgery, University of Arizona, Tucson, AZ, USA.
Narong
N
Kulvatunyou
Department of Surgery, University of Arizona, Tucson, AZ, USA.
Julie
J
Wynne
Department of Surgery, University of Arizona, Tucson, AZ, USA.
Rifat
R
Latifi
Department of Surgery, University of Arizona, Tucson, AZ, USA.
Peter
P
Rhee
Department of Surgery, University of Arizona, Tucson, AZ, USA. tokeeffe@surgery.arizona.edu.
Terence
T
O'Keeffe
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D000070642:Brain Injuries, Traumatic / Q000150:complications*; D018890:Chemoprevention; D016208:Databases, Factual; D005260:Female; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000031:analogs & derivatives / Q000627:therapeutic use; D010889:Piracetam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D057216:Propensity Score; D012189:Retrospective Studies; D012640:Seizures / Q000209:etiology / Q000517:prevention & control*; D017211:Treatment Failure; D055815:Young Adult
D000927:Anticonvulsants; D000077287:Levetiracetam; D010672:Phenytoin; C043114:fosphenytoin; D010889:Piracetam